

# Whole Genome Sequencing Unravels Complex Structural Rearrangement Undetectable by Exome Sequencing

CASE STUDY



## Clinical Scenario

- > 6-month-old female presents with a clinical diagnosis of oculocutaneous albinism<sup>1</sup>
- > Prior workup included albinism panel testing at two different clinical laboratories, with deletion/duplication included in the second panel
- > Both panels indicated carrier status for oculocutaneous albinism II as a result of a heterozygous *OCA2* pathogenic variant (c.1465A>G (p.Asn489Asp))

## Clinical Features

Hypopigmentation  
Nystagmus



## Genetic Testing

Provider ordered **GenomeNext**

Whole-genome sequencing (WGS) performed to check for a potential missed pathogenic variant in *OCA2*

### RESULT DETAILS

- Identified a second pathogenic variant in trans with the previously identified pathogenic *OCA2* variant (c.1465A>G (p.Asn489Asp)).
- Second pathogenic variant was a complex copy neutral rearrangement: a deletion and inverted reinsertion of exons 3-19 within intron 1.
- This complex rearrangement accounts for 2-3% of pathogenic *OCA2* variants.<sup>2</sup> It is undetectable by exome sequencing because it is a deep intronic rearrangement (all breakpoints are in introns) that maintains a copy number neutral exonic sequence.

## Using WGS to Provide More Answers

Identification of a second pathogenic variant confirmed the genetic basis of the clinical diagnosis.

Family used this information to pursue in-vitro fertilization and perform preimplantation genetic testing for a subsequent pregnancy.



## Points For Your Practice



Recognize that traditional exome sequencing detects up to 85% of pathogenic variants<sup>3</sup> but frequently misses complex structural rearrangements.



Consider utilizing WGS as a first-tier diagnostic tool or a follow-up for negative exome results to achieve more comprehensive variant detection across both coding and non-coding regions.

Based on information from an actual patient case; individual identifiers have been modified to protect patient privacy

### References

1. Berger SI, Pitsava G, Cohen AJ, et al. Increased diagnostic yield from negative whole genome-slice panels using automated reanalysis. *Clin Genet.* 2023;104(3):377-383. doi:10.1111/cge.14360
2. Loftus SK, Lundh L, Watkins-Chow DE, et al. A custom capture sequence approach for oculocutaneous albinism identifies structural variant alleles at the *OCA2* locus. *Hum Mutat.* 2021;42(10):1239-1253. doi:10.1002/humu.24257
3. <https://www.illumina.com/techniques/sequencing/dna-sequencing/targeted-resequencing/exome-sequencing.html>

1 Enterprise, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 [ambrygen.com](http://ambrygen.com)

©2026 Ambry Genetics Corporation. All rights reserved. Ambry Genetics<sup>®</sup> is a registered trademark of Ambry Genetics Corporation.

MKT-SPEC-FLYR-40048-EN v2 06.09.26